Top

International Journal of Colorectal Disease

Published in:

01-02-2010 | Original Article

Differential effects of NOD2 polymorphisms on colorectal cancer risk: a meta-analysis

Authors: Yun Tian, Yi Li, Zhenhua Hu, Daqing Wang, Xiyang Sun, Changshan Ren

Published in: International Journal of Colorectal Disease | Issue 2/2010

Abstract

Introduction

Since Kurzawski et al. described an association between the 3020insC NOD2 single nucleotide polymorphism and the risk of colorectal cancer(CRC) in 2004, reports published in the past several years have controversial results regarding the relationship between the development of CRC and NOD2 gene polymorphisms. To clarify the potential role of NOD2 P286S, R702W, G908R, and 3020insC polymorphisms in CRC patients, we have undertaken a systematic review and meta-analysis of published articles.

Materials and methods

Studies reporting on NOD2 polymorphisms and CRC were searched in the PubMed, EMBASE, and the Science Citation Index from the inception of each database to May, 2009. The search strategy included the keywords “CRC”, “colon cancer”, “rectal cancer”, “polymorphism”, and “NOD2/CARD15”.

Result

Eight eligible case-control studies about Caucasians from four countries contributed data on 5,888 subjects (cases: 3,524; controls: 2,364). Compared to the wild genotype, the R702W, G908R, and 3020insC polymorphisms were associated with an increased risk of CRC (odds ratio (OR): 1.59, 1.98, 1.44; 95% confidence interval (CI): 1.09–2.32, 1.14–3.44, 1.13–1.84; P = 0.02, 0.01, 0.003). However, P268S polymorphism did not influence CRC risk (OR: 1.27; CI: 0.32–5.00; P = 0.73).

Conclusions

These findings indicate that NOD2 R702W, G908R, and 3020insC polymorphisms contribute to CRC susceptibility in Caucasians. Meta-analysis of these polymorphisms in NOD2 gene will help determine their role in CRC carcinogenesis.

Capurso G, Marignani M, Delle Fave G (2006) Probiotics and the incidence of colorectal cancer: when evidence is not evident. Dig Liver Dis 38(Suppl 2):S277–S282CrossRefPubMed

Kim HJ, Yu MH, Kim H, Byun J, Lee C (2008) Noninvasive molecular biomarkers for the detection of colorectal cancer. BMB Rep 41:685–692PubMed

Loffler I, Grun M, Bohmer FD, Rubio I (2008) Role of cAMP in the promotion of colorectal cancer cell growth by prostaglandin E2. BMC Cancer 8:380CrossRefPubMed

Takahashi H, Inamori M (2009) Lifestyle-related disease and colorectal cancer. Intern Med 48:121CrossRefPubMed

Kasztelan-Szczerbinska B, Cichoz-Lach H, Slomka M (2008) Colorectal cancer as a health care problem: evaluation of the current diagnostic options. Pol Arch Med Wewn 118:224–227PubMed

Velculescu VE (2008) Defining the blueprint of the cancer genome. Carcinogenesis 29:1087–1091CrossRefPubMed

Hisamuddin IM, Yang VW (2004) Genetics of colorectal cancer. MedGenMed 6:13PubMed

Cheah PY (2009) Recent advances in colorectal cancer genetics and diagnostics. Crit Rev Oncol Hematol 69:45–55CrossRefPubMed

Chu E (2009) Clinical colorectal cancer: "2008—the year in review". Clin Colorectal Cancer 8:9–10CrossRefPubMed

10.

Hampe J, Cuthbert A, Croucher PJ, Mirza MM, Mascheretti S, Fisher S et al (2001) Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 357:1925–1928CrossRefPubMed

11.

Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J et al (2001) Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411:599–603CrossRefPubMed

12.

Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R et al (2001) A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature 411:603–606CrossRefPubMed

13.

Inohara C, McDonald C, Nunez G (2005) NOD-LRR proteins: role in host-microbial interactions and inflammatory disease. Annu Rev Biochem 74:355–383CrossRefPubMed

14.

Girardin SE, Boneca IG, Viala J, Chamaillard M, Labigne A, Thomas G et al (2003) Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 278:8869–8872CrossRefPubMed

15.

Inohara N, Nunez G (2001) The NOD: a signaling module that regulates apoptosis and host defense against pathogens. Oncogene 20:6473–6481CrossRefPubMed

16.

Inohara N, Ogura Y, Fontalba A, Gutierrez O, Pons F, Crespo J et al (2003) Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J Biol Chem 278:5509–5512CrossRefPubMed

17.

Girardin SE, Tournebize R, Mavris M, Page AL, Li X, Stark GR et al (2001) CARD4/Nod1 mediates NF-kappaB and JNK activation by invasive Shigella flexneri. EMBO Rep 2:736–742CrossRefPubMed

18.

Angeletti S, Galluzzo S, Santini D, Ruzzo A, Vincenzi B, Ferraro E et al (2009) NOD2/CARD15 polymorphisms impair innate immunity and increase susceptibility to gastric cancer in an Italian population. Hum Immunol 70(9):729–732CrossRefPubMed

19.

Jackson JR, Seed MP, Kircher CH, Willoughby DA, Winkler JD (1997) The codependence of angiogenesis and chronic inflammation. FASEB J 11:457–465PubMed

20.

Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ (2000) Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res 60:184–190PubMed

21.

Nakajima N, Kuwayama H, Ito Y, Iwasaki A, Arakawa Y (1997) Helicobacter pylori, neutrophils, interleukins, and gastric epithelial proliferation. J Clin Gastroenterol 25(Suppl 1):S198–S202CrossRefPubMed

22.

Bernstein CN, Blanchard JF, Kliewer E, Wajda A (2001) Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 91:854–862CrossRefPubMed

23.

Jess T, Gamborg M, Matzen P, Munkholm P, Sorensen TI (2005) Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol 100:2724–2729CrossRefPubMed

24.

Leshinsky-Silver E, Karban A, Buzhakor E, Fridlander M, Yakir B, Eliakim R et al (2005) Is age of onset of Crohn's disease governed by mutations in NOD2/caspase recruitment domains 15 and Toll-like receptor 4? Evaluation of a pediatric cohort. Pediatr Res 58:499–504CrossRefPubMed

25.

Alhopuro P, Ahvenainen T, Mecklin JP, Juhola M, Jarvinen HJ, Karhu A et al (2004) NOD2 3020insC alone is not sufficient for colorectal cancer predisposition. Cancer Res 64:7245–7247CrossRefPubMed

26.

Kurzawski G, Suchy J, Kladny J, Grabowska E, Mierzejewski M, Jakubowska A et al (2004) The NOD2 3020insC mutation and the risk of colorectal cancer. Cancer Res 64:1604–1606CrossRefPubMed

27.

Lakatos PL, Hitre E, Szalay F, Zinober K, Fuszek P, Lakatos L et al (2007) Common NOD2/CARD15 variants are not associated with susceptibility or the clinicopathologic characteristics of sporadic colorectal cancer in Hungarian patients. BMC Cancer 7:54CrossRefPubMed

28.

Papaconstantinou I, Theodoropoulos G, Gazouli M, Panoussopoulos D, Mantzaris GJ, Felekouras E et al (2005) Association between mutations in the CARD15/NOD2 gene and colorectal cancer in a Greek population. Int J Cancer 114:433–435CrossRefPubMed

29.

Roberts RL, Gearry RB, Allington MD, Morrin HR, Robinson BA, Frizelle FA (2006) Caspase recruitment domain-containing protein 15 mutations in patients with colorectal cancer. Cancer Res 66:2532–2535CrossRefPubMed

30.

Suchy J, Klujszo-Grabowska E, Kladny J, Cybulski C, Wokolorczyk D, Szymanska-Pasternak J et al (2008) Inflammatory response gene polymorphisms and their relationship with colorectal cancer risk. BMC Cancer 8:112CrossRefPubMed

31.

Szeliga J, Sondka Z, Jackowski M, Jarkiewicz-Tretyn J, Tretyn A, Malenczyk M (2008) NOD2/CARD15 polymorphism in patients with rectal cancer. Med Sci Monit 14:CR480–CR484PubMed

32.

Tuupanen S, Alhopuro P, Mecklin JP, Jarvinen H, Aaltonen LA (2007) No evidence for association of NOD2 R702W and G908R with colorectal cancer. Int J Cancer 121:76–79CrossRefPubMed

33.

Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF (1999) Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 354:1896–1900CrossRefPubMed

34.

Hampe J, Grebe J, Nikolaus S, Solberg C, Croucher PJ, Mascheretti S et al (2002) Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study. Lancet 359:1661–1665CrossRefPubMed

35.

Inohara N, Ogura Y, Chen FF, Muto A, Nunez G (2001) Human Nod1 confers responsiveness to bacterial lipopolysaccharides. J Biol Chem 276:2551–2554CrossRefPubMed

36.

Ogura Y, Inohara N, Benito A, Chen FF, Yamaoka S, Nunez G (2001) Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J Biol Chem 276:4812–4818CrossRefPubMed

37.

Chen F, Castranova V, Shi X (2001) New insights into the role of nuclear factor-kappaB in cell growth regulation. Am J Pathol 159:387–397PubMed

38.

Dejardin E, Deregowski V, Chapelier M, Jacobs N, Gielen J, Merville MP et al (1999) Regulation of NF-kappaB activity by I kappaB-related proteins in adenocarcinoma cells. Oncogene 18:2567–2577CrossRefPubMed

39.

Gilmore TD, Koedood M, Piffat KA, White DW (1996) Rel/NF-kappaB/IkappaB proteins and cancer. Oncogene 13:1367–1378PubMed

40.

Mukhopadhyay T, Roth JA, Maxwell SA (1995) Altered expression of the p50 subunit of the NF-kappa B transcription factor complex in non-small cell lung carcinoma. Oncogene 11:999–1003PubMed

41.

Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM et al (1997) Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 100:2952–2960CrossRefPubMed

42.

Huzarski T, Lener M, Domagala W, Gronwald J, Byrski T, Kurzawski G et al (2005) The 3020insC allele of NOD2 predisposes to early onset breast cancer. Breast Cancer Res Treat 89:91–93CrossRefPubMed

43.

Rothman N, Skibola CF, Wang SS, Morgan G, Lan Q, Smith MT et al (2006) Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 7:27–38CrossRefPubMed

44.

Yang SK, Loftus EV Jr, Sandborn WJ (2001) Epidemiology of inflammatory bowel disease in Asia. Inflamm Bowel Dis 7:260–270CrossRefPubMed

45.

Inoue N, Tamura K, Kinouchi Y, Fukuda Y, Takahashi S, Ogura Y et al (2002) Lack of common NOD2 variants in Japanese patients with Crohn’s disease. Gastroenterology 123:86–91CrossRefPubMed

46.

Cavanaugh JA, Adams KE, Quak EJ, Bryce ME, O'Callaghan NJ, Rodgers HJ et al (2003) CARD15/NOD2 risk alleles in the development of Crohn's disease in the Australian population. Ann Hum Genet 67:35–41CrossRefPubMed

47.

Andersen V, Agerstjerne L, Jensen D, Ostergaard M, Saebo M, Hamfjord J et al (2009) The multidrug resistance 1 (MDR1) gene polymorphism G-rs3789243-A is not associated with disease susceptibility in Norwegian patients with colorectal adenoma and colorectal cancer; a case control study. BMC Med Genet 10:18CrossRefPubMed

48.

Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Kearney J et al (1994) A prospective study of cigarette smoking and risk of colorectal adenoma and colorectal cancer in U.S. men. J Natl Cancer Inst 86:183–191CrossRefPubMed

49.

Ernst A, Jacobsen B, Ostergaard M, Okkels H, Andersen V, Dagiliene E et al (2007) Mutations in CARD15 and smoking confer susceptibility to Crohn's disease in the Danish population. Scand J Gastroenterol 42:1445–1451CrossRefPubMed

50.

Hansen RD, Sorensen M, Tjonneland A, Overvad K, Wallin H, Raaschou-Nielsen O et al (2008) A haplotype of polymorphisms in ASE-1, RAI and ERCC1 and the effects of tobacco smoking and alcohol consumption on risk of colorectal cancer: a Danish prospective case-cohort study. BMC Cancer 8:54CrossRefPubMed

51.

Anderson JC, Attam R, Alpern Z, Messina CR, Hubbard P, Grimson R et al (2003) Prevalence of colorectal neoplasia in smokers. Am J Gastroenterol 98:2777–2783CrossRefPubMed

52.

Liang PS, Chen TY, Giovannucci E (2009) Cigarette smoking and colorectal cancer incidence and mortality: systematic review and meta-analysis. Int J Cancer 124:2406–2415CrossRefPubMed

53.

Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M et al (2000) Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343:78–85CrossRefPubMed

54.

Aaltonen L, Johns L, Jarvinen H, Mecklin JP, Houlston R (2007) Explaining the familial colorectal cancer risk associated with mismatch repair (MMR)-deficient and MMR-stable tumors. Clin Cancer Res 13:356–361CrossRefPubMed

55.

Houlston RS, Webb E, Broderick P, Pittman AM, Di Bernardo MC, Lubbe S et al (2008) Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nat Genet 40:1426–1435CrossRefPubMed

56.

Tomlinson I, Webb E, Carvajal-Carmona L, Broderick P, Kemp Z, Spain S et al (2007) A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nat Genet 39:984–988CrossRefPubMed

57.

Zanke BW, Greenwood CM, Rangrej J, Kustra R, Tenesa A, Farrington SM et al (2007) Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nat Genet 39:989–994CrossRefPubMed

58.

Tomlinson IP, Webb E, Carvajal-Carmona L, Broderick P, Howarth K, Pittman AM et al (2008) A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat Genet 40:623–630CrossRefPubMed

59.

Tenesa A, Farrington SM, Prendergast JG, Porteous ME, Walker M, Haq N et al (2008) Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nat Genet 40:631–637CrossRefPubMed

60.

Jaeger E, Webb E, Howarth K, Carvajal-Carmona L, Rowan A, Broderick P et al (2008) Common genetic variants at the CRAC1 (HMPS) locus on chromosome 15q13.3 influence colorectal cancer risk. Nat Genet 40:26–28CrossRefPubMed

61.

Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K (2002) A comprehensive review of genetic association studies. Genet Med 4:45–61CrossRefPubMed

62.

Ioannidis JP (2003) Genetic associations: false or true? Trends Mol Med 9:135–138CrossRefPubMed

63.

Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG (2001) Replication validity of genetic association studies. Nat Genet 29:306–309CrossRefPubMed

64.

Guo QS, Xia B, Jiang Y, Qu Y, Li J (2004) NOD2 3020insC frameshift mutation is not associated with inflammatory bowel disease in Chinese patients of Han nationality. World J Gastroenterol 10:1069–1071PubMed

Title: Differential effects of NOD2 polymorphisms on colorectal cancer risk: a meta-analysis
Authors: Yun Tian
Yi Li
Zhenhua Hu
Daqing Wang
Xiyang Sun
Changshan Ren
Publication date: 01-02-2010
Publisher: Springer-Verlag
Published in: International Journal of Colorectal Disease / Issue 2/2010
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-009-0809-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Differential effects of NOD2 polymorphisms on colorectal cancer risk: a meta-analysis

Abstract

Introduction

Materials and methods

Result

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Materials and methods

Result

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2010

Erratum to: Comparison of a colonic J-pouch and transverse coloplasty pouch in patients with rectal cancer after an ultralow anterior resection using fecoflowmetric profiles

Covering the colon anastomoses with amniotic membrane prevents the negative effects of early intraperitoneal 5-FU administration on anastomotic healing

MICB0106 gene polymorphism is associated with ulcerative colitis in central China

Anal physiology testing in fecal incontinence: is it of any value?

A meta-analysis on XRCC1 and XRCC3 polymorphisms and colorectal cancer risk

Krukenberg tumors of colorectal origin: a dismal outcome—experience of a tertiary center